Accuray is a radiation oncology company that develops, manufactures, and sells innovative treatment solutions that set the standard of care with the goal of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. Its portfolio of products include the TomoTherapy H Series and the CyberKnife M6 Series.
The company reported today that Lancaster General Health in Pennsylvania is the first U.S. center to treat a patient with the CyberKnife M6 System. This is the most advanced robotic radiosurgery system in the world and the latest generation of its CyberKnife System. In addition to real-time tracking and automatic correction for tumor motion, the redesigned system can redirect beams from a wider angle around the patient and provides a streamlined user interface for treatment delivery.
The M6 was designed to provide clinicians with enhanced stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) solutions that target tumors non-invasively with precisely delivered, high doses of radiation that spare healthy tissue and minimize disruption to patients’ lives. Accuray’s CyberKnife M6 System is a non-surgical option for patients that have inoperable or surgically complex tumors, or who are seeking an alternative to surgery.
The bottom line is that the new CyberKnife M6 System enables the precise radiosurgical treatment of tumors anywhere in the body with minimal radiation exposure to surrounding healthy tissues and organs. For further information about Accuray and its CyberKnife technology, please visit www.accuray.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
